Rovira A, et al. – Here, the clinicians intended to compare detection of gadolinium– enhancing lesions or active disease following a single or cumulative dose of a macrocyclic gadolinium–based contrast agent with different image acquisition delays in patients with clinically isolated syndrome or relapsing multiple sclerosis. Clinicians exhibited evidence that cumulative dosing of a macrocyclic gadolinium–based contrast agent increases detection of enhancing lesions and patients with active lesions. These findings could be considered in the design of MR imaging protocols aimed at detecting active multiple sclerosis lesions.